Form 4: Cytokinetics Director Lynne Parshall Exercises Options and Sells Shares
SEC Form 4 Filing
Director Lynne Parshall exercised stock options and sold shares of Cytokinetics on June 17, 2024.
Summary
- On June 17, 2024, Lynne Parshall, a director of Cytokinetics Inc., exercised non-qualified stock options to acquire 5,000 shares of common stock at a price of $10.68 per share.
- On the same day, Ms. Parshall sold 5,000 shares of Cytokinetics common stock at a price of $52.55 per share.
- Following these transactions, Ms. Parshall directly owns 20,600 shares of Cytokinetics common stock and 10,000 non-qualified stock options.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock transactions. The director exercised options and sold shares, which could be interpreted in various ways but doesn't inherently indicate positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of stock transactions by a company insider, providing transparency to investors about the trading activities of key personnel.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 06/17/2019 | Date exercisable for Non-Qualified Stock Option (Right to Buy) |
| 05/14/2029 | Expiration date for Non-Qualified Stock Option (Right to Buy) |
| 06/17/2024 | Date of transaction: Lynne Parshall exercised stock options and sold shares of Cytokinetics. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.